Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine discusses key takeaways from the ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions.

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives. This has been a uniquely difficult issue in the weight-loss ...

Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...